Clinical features of patients with allergic reactions induced by hepatic arterial perfusion chemotherapy and its nursing strategy:preliminary results in 82 patients / 介入放射学杂志

Objective To investigate the clinical features of patients with allergic reactions induced by hepatic arterial perfusion chemotherapy,and to discuss its nursing strategy.Methods The clinical manifestations,severity grading,time of onset,high-risk drugs,and the initial symptom of anaphylactic shock in 82 patients with allergic reactions were analyzed.Results Of the 82 patients,57(69.5％)had liver metastases from colorectal cancer,aged 42-82 years.Most patients(98.8％)were allergic to oxaliplatin.Degree I allergic reaction was most commonly seen(80.5％),and the clinical manifestations were mainly skin symptoms.Multiple symptoms could occur at the same time.The allergic reactions could occur in various time periods of medication,and anaphylactic shock usually occurred within 30 min after medication,and the initial symptom was atypical.Conclusion Oxaliplatin is a common drug that may cause allergic reactions in patients receiving hepatic artery infusion chemotherapy.Nursing staff should be familiar with the relevant drug allergic reactions,especially the clinical symptoms,features,and nursing measures of anaphylactic shock,so as to ensure the safety of patients.(J Intervent Radiol,2023,32:1242-1245)

Clinical efficacy of hepatic artery infusion chemotherapy combined with immunotherapy plus target therapy for advanced hepatocellular carcinoma / 中华消化外科杂志

Primary liver cancer is one of the common malignant tumors and its mortality ranks third in the world. Because there are no obvious symptoms in the early stage of liver cancer, most patients are diagnosed as advanced stage, without the opportunity of surgical resection. The authors report a case of hepatocellular carcinoma with portal vein tumor thrombus, which reduced significantly after hepatic artery infusion chemotherapy combined with bevacizumab and atezolizumab, showing the safety and efficacy.

Clinical research of prophylactic hepatic artery infusion chemotherapy af-ter curative resection in patients with pancreatic cancer / 中国现代医生

Objective To explore the effect of prophylactic hepatic artery infusion chemotherapy (HAIC) on survival after curative resection in patients with primary pancreatic cancer. Methods A total of 106 patients with pancreatic cancer after pancreatectomy received 2 cycles of HAIC plus 4 cycles of systemic chemotherapy (HAIC) or 6 cycles of sys-temic chemotherapy alone (Control). Both the HAIC and systemic chemotherapy regimen consisted of 5-fluorouracil 1000 mg/m2 on day 1 and Gemcitabine 800 mg/m2 on day 1 and 8. The treatment was started on an average of 3 weeks after surgery and repeated every 4 weeks. The disease-free survival , overall survival and liver metastases-free survival were compared. Results Significant differences were found in 3-year overall survival (HAIC, 23.08 %; Control, 14.81%;P=0.0473) and liver metastases-free survival (HAIC, 80.77%;Control, 55.56%;P=0.0014). There was no significant difference in adverse effects between two groups. Conclusion HAIC effectively and safely prevented liver metastases and improved the prognosis of patients with pancreatic cancer after pancreatectomy.